Tamoxifen, mammographic density, and breast cancer prevention

Journal of the National Cancer Institute

Volumn 103, Issue 9, 2011, Pages 704-705

  Boyd, Norman F ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; HUMAN; MAMMOGRAPHY; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MAMMOGRAPHY; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 79955756153     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr115     Document Type: Editorial

References (27)

1. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005; 97 ( 10 ): 715-723. (Pubitemid 40872378)
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356 ( 23 ): 2388-2398. (Pubitemid 46883773)
3. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81 ( 24 ): 1879-1886. (Pubitemid 20026073)
4. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15 ( 6 ): 1159-1169.
5. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006; 98 ( 17 ): 1215-1226. (Pubitemid 44390992)
6. Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011; 103 ( 9 ): 744-752.
7. Boyd NF, Martin LJ, Bronskill MJ, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst. 2010; 102 ( 16 ): 1224-1237.
8. Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev. 2000; 9 ( 9 ): 911-915.
9. Martin LJ, Boyd N. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res. 2008; 10 ( 1 ): 1-14.
10. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003; 95 ( 1 ): 30-37. (Pubitemid 36124293)
11. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999; 181 ( 2 ): 348-352. (Pubitemid 29409912)
12. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001; 285 ( 2 ): 171-176. (Pubitemid 32048518)
13. Chlebowski RT, Hendrix SL, Langer R, et al. Infl uence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA. 2003; 289 ( 24 ): 3243-3253. (Pubitemid 37430077)
14. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007; 99 ( 15 ): 1178-1187. (Pubitemid 47233068)
15. Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K. Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13 ( 12 ): 2090-2095. (Pubitemid 40054303)
16. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst. 1990; 82 ( 21 ): 1693-1697.
17. Prentice RL. Surrogate endpoints in clinical trials: defi nition and operational criteria. Stat Med. 1988; 8 ( 4 ): 431-440. (Pubitemid 19105891)
18. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev. 2002; 2 ( 1 ): 19-27. (Pubitemid 37328804)
19. Wolfe JN. Breast parenchymal patterns and their changes with age. Radiology. 1976; 121 ( 3, pt 1 ): 545-552.
20. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet. 2005; 6 ( 10 ): 798-808. (Pubitemid 41430721)
21. Brisson J, Morrison AS, Kopans DB. Height and weight, mammographic features of breast tissue, and breast cancer risk. Am J Epidemiol. 1984; 119 ( 3 ): 371-381. (Pubitemid 14154480)
22. Grove JS, Goodman MJ, Gilbert F, Mi MP. Factors associated with mam-mographic pattern. Br J Radiol. 1985; 58 ( 685 ): 21-25.
23. Lawlor DA, Okasha M, Gunnell D, Smith GD, Ebrahim S. Associations of adult measures of childhood growth with breast cancer: fi ndings from the British Women's Heart and Health Study. Br J Cancer. 2003; 89 ( 1 ): 81-87. (Pubitemid 36897940)
24. Hunter DJ, Willett WC. Diet, body size, and breast cancer. Epidemiol Rev. 1993; 15 ( 1 ): 110-132. (Pubitemid 23269075)
25. Ekbom A, Thurfjell E, Hsieh CC, Trichopoulos D, Adami HO. Perinatal characteristics and adult mammographic patterns. Int J Cancer. 1995; 61 ( 2 ): 177-180.
26. Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev. 2001; 10 ( 4 ): 287-301. (Pubitemid 32703212)
27. Woolcott CG, Courneya KS, Boyd NF, et al. Mammographic density change with 1 year of aerobic exercise among postmenopausal women: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2010; 19 ( 4 ): 1112-1121.